Skip to content

Opening book details…

Can I read Re-definition and supporting evidence toward Fanconi Anemia as a mitochondrial disease: Prospects for new design in clinical management on EtoBox?

Re-definition and supporting evidence toward Fanconi Anemia as a mitochondrial disease: Prospects for new design in clinical management by Giovanni Pagano; Luca Tiano; Federico V. Pallardó; Alex Lyakhovich; Sudit S. Mukhopadhyay; Paolo Di Bartolomeo; Adriana Zatterale; Marco Trifuoggi is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Re-definition and supporting evidence toward Fanconi Anemia as a mitochondrial disease: Prospects for new design in clinical management about?

Fanconi anemia (FA) has been investigated since early studies based on two definitions, namely defective DNA repair and proinflammatory condition. The former definition has built up the grounds for FA diagnosis as excess sensitivity of patients’ cells to xenobiotics as diepoxybutane and mitomycin C, resulting in typical chromosomal abnormalities. Another line of studies has related FA phenotype to a prooxidant state, as detected by both __in vitro__ and __ex vivo__ studies. The discovery that the FA group G (FANCG) protein is found in mitochondria (Mukhopadhyay et al., 2006) has been followed by an extensive line of studies providing evidence for multiple links between other FA gene products and mitochondrial dysfunction. The fact that FA proteins are encoded by nuclear, not mitochondrial DNA does not prevent these proteins to hamper mitochondrial function, as it is recognized that most mitochondrial proteins are of nuclear origin. This body of evidence supporting a central role of mitochondrial dysfunction, along with redox imbalance in FA, should lead to the re-definition of FA as a mitochondrial disease. A body of literature has demonstrated the beneficial effects of mitochondri

Who reads Re-definition and supporting evidence toward Fanconi Anemia as a mitochondrial disease: Prospects for new design in clinical management?

It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.

Author
Giovanni Pagano; Luca Tiano; Federico V. Pallardó; Alex Lyakhovich; Sudit S. Mukhopadhyay; Paolo Di Bartolomeo; Adriana Zatterale; Marco Trifuoggi
Publisher
Elsevier BV
Published
2021
Language
EN
Field
Biochemistry, Genetics and Molecular Biology (Life Sciences)

More by Giovanni Pagano; Luca Tiano; Federico V. Pallardó; Alex Lyakhovich; Sudit S. Mukhopadhyay; Paolo Di Bartolomeo; Adriana Zatterale; Marco Trifuoggi

Browse all works by Giovanni Pagano; Luca Tiano; Federico V. Pallardó; Alex Lyakhovich; Sudit S. Mukhopadhyay; Paolo Di Bartolomeo; Adriana Zatterale; Marco Trifuoggi